TITLE

PI-62

AUTHOR(S)
Tham, L.; Goh, B.; Wang, L.; Yong, W.; Wong, C.; Lee, S.; Soo, R.; Sukri, N.; Lee, H. S.
PUB. DATE
February 2006
SOURCE
Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background/aims: Midazolam (MDZ) clearance (CL) has shown correlation with docetaxel (DOC) CL. This study compared MDZ-phenotyping of DOC CL with and without keotconazole (KETO) inhibition of CYP3A.Methods: In this open-label study, the pharmacokinetics of MDZ and DOC and their correlations were compared with (n = 45) and without KETO inhibition (n= 33). DOC and MDZ doses for the control versus KETO-modulated group were 75-100mg/m2 versus 16.5-70mg and IV 2.5mg versus 1mg respectively. Plasma-concentrations time-profiles were analyzed by noncompartmental method. Main OH-metabolites:parent ratios for MDZ and DOC were examined to confirm CYP3A inhibition.Results: Mean MDZ CL showed a 6-fold reduction in CL with KETO and significance for variance reduction (p<0.0001). 1'OH MDZ/MDZ ratios were highly significant (p<0.0001) with control being 11.8 (15 mins), 10.9 (1h), 11.1 (2h) and 10.2 (5h) times higher. Mean DOC CL showed a 1.8-fold reduction but not its variance (p=0.179). The metabolite ratios of M4/DOC and M1+M3/DOC were 2.4 (p< 0.001) and 1.7 (p = 0.005) times higher with control, at 1h, and 2.7 (p = 0.015) and 1.5 (p = 0.684) times higher at 2h. Correlation between MDZ and DOC CLs was lost in the ketoconazole group (r = 0.184, p = 0.263) but modest correlation was found with creatinine CL (r=0.484, p=0.002) instead.Conclusions: KETO reduced MDZ and DOC CLs to different extents. MDZ CL became more predictable but DOC CL remained highly variable. MDZ is unsuitable for phenotyping DOC under KETO-modulation.Clinical Pharmacology & Therapeutics (2005) 79, P23–P23; doi: 10.1016/j.clpt.2005.12.083
ACCESSION #
22412453

 

Related Articles

  • PI-62. Tham, L.; Goh, B.; Wang, L.; Yong, W.; Wong, C.; Lee, S.; Soo, R.; Sukri, N.; Lee, H. S. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP23 

    Background/aims: Midazolam (MDZ) clearance (CL) has shown correlation with docetaxel (DOC) CL. This study compared MDZ-phenotyping of DOC CL with and without keotconazole (KETO) inhibition of CYP3A.Methods: In this open-label study, the pharmacokinetics of MDZ and DOC and their correlations were...

  • Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data. Templeton, I.; Peng, C.-C.; Thummel, K. E.; Davis, C.; Kunze, K. L.; Isoherranen, N. // Clinical Pharmacology & Therapeutics;Oct2010, Vol. 88 Issue 4, p499 

    Inhibitory drug metabolites may contribute to drug-drug interactions (DDIs). The aim of this study was to determine the importance of inhibitory metabolites of itraconazole (ITZ) in in vivo cytochrome P450 (CYP) 3A4 inhibition. The pharmacokinetics of ITZ and midazolam (MDZ) were determined in...

  • A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Wei-Peng Yong; Ling-Zhi Wang; Lai-San Tham; Chiung-Ing Wong; Soo-Chin Lee; Ross Soo; Sukri, Norita; How-Sung Lee; Boon-Cher Goh // Cancer Chemotherapy & Pharmacology;Jul2008, Vol. 62 Issue 2, p243 

    The aims were to determine the maximum tolerable dose (MTD) of docetaxel with CYP3A inhibition by ketoconazole, and to correlate the pharmacokinetics of docetaxel with midazolam phenotyping of CYP3A activity. Forty-one patients with refractory metastatic cancers were treated with an escalating...

  • Midazolam and its metabolites in brain death diagnosis. Meinitzer, A.; Zink, M.; März, W.; Baumgartner, A.; Halwachs-baumann, G. // International Journal of Clinical Pharmacology & Therapeutics;2005, Vol. 43 Issue 11, p517 

    Objective: There is only limited knowledge on the pharmacokinetics of midazolam and its active metabolites in potential organ donors. Be fore establishing the diagnosis of brain death, drugs interfering with the neurological assessment have to be washed out. National guide lines advise a waiting...

  • General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs. Ohno, Yoshiyuki; Hisaka, Akihiro; Suzuki, Hiroshi // Clinical Pharmacokinetics;2007, Vol. 46 Issue 8, p681 

    Background: Cytochrome P450 (CYP) 3A4 is the most prevalent metabolising enzyme in the human liver and is also a target for various drug interactions of significant clinical concern. Even though there are numerous reports regarding drug interactions involving CYP3A4, it is far from easy to...

  • Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. Lim, Y.-W.; Goh, B.-C.; Wang, L.-Z.; Tan, S.-H.; Chuah, B. Y. S.; Lim, S.-E.; Iau, P.; Buhari, S. A.; Chan, C.-W.; Sukri, N. B.; Cordero, M. T.; Soo, R.; Lee, S.-C. // Annals of Oncology;Nov2010, Vol. 21 Issue 11, p2175 

    Background: We previously found 70 mg flat-dose docetaxel coadministered with ketoconazole to modulate CYP3A4 to be the maximum tolerated dose that resulted in comparable docetaxel area under the plasma concentration–time curve (AUC) as 75–100 mg/m2 docetaxel.Patients and methods:...

  • Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Tan, Antoinette; Gibbon, Darlene; Stein, Mark; Lindquist, Diana; Edenfield, Jeffery; Martin, Julie; Gregory, Charles; Suttle, A.; Tada, Hiroomi; Botbyl, Jeffrey; Stephenson, Joseph // Cancer Chemotherapy & Pharmacology;Jun2013, Vol. 71 Issue 6, p1635 

    Purpose: The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its bioavailability. This study evaluated the effect of a potent CYP3A4 inhibitor, ketoconazole, and the proton pump inhibitor esomeprazole...

  • Desloratadine Has No Clinically Relevant Electrocardiographic or Pharmacodynamic Interactions with Ketoconazole. Banfield, C.; Herron, J.; Keung, A.; Padhi, D.; Affrime, M. // Clinical Pharmacokinetics;2002 Supplement, Vol. 41 Issue 10, p37 

    Objective: This study was performed to assess the electrocardiographic safety and pharmacokinetics of desloratadine in combination with the CYP3A4 inhibitor ketoconazole. Design: A randomised, placebo-controlled, third-party-blind, 2-way crossover study. Participants: 24 healthy volunteers (12...

  • Midazolam Metabolism: Implications for Individualised Dosing? Roberts, Jason A.; Coulthard, Mark G.; Addison, Russell S.; Foot, Carole; Lipman, Jeffrey // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 3, p198 

    Aim: To compare the clearance of midazolam and its metabolites in critically ill paediatric and adult patients. Method: A prospective study conducted in paediatric and adult intensive care units. Patients over 2 years of age receiving midazolam for therapeutic sedation were eligible for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics